W Jeffrey Petty

Author PubWeight™ 13.24^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.	J Clin Oncol	2012	1.84
2	Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy.	Clin Cancer Res	2004	1.68
3	Bexarotene and erlotinib for aerodigestive tract cancer.	J Clin Oncol	2005	1.30
4	Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.	J Clin Oncol	2009	1.26
5	The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database.	Cancer	2007	1.21
6	A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.	Clin Cancer Res	2007	1.04
7	Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention.	Cancer Res	2004	0.95
8	Retinoid targets in cancer therapy and chemoprevention.	Cancer Biol Ther	2003	0.86
9	Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke.	Lung Cancer	2010	0.84
10	Effects of continued tobacco use during treatment of lung cancer.	Expert Rev Anticancer Ther	2010	0.83
11	Distinct functions of retinoic acid receptor beta isoforms: implications for targeted therapy.	Endocr Metab Immune Disord Drug Targets	2008	0.80
12	Nonclassical retinoids and lung carcinogenesis.	Clin Lung Cancer	2005	0.78